Peter Casasanto
Corporate Officer/Principal en SOPHIA GENETICS SA .
Perfil
Peter Casasanto is currently the Chief BioPharma Officer at SOPHiA GENETICS SA since 2022.
Previously, he worked as the Vice President-New Commercialization Initiatives at CellCarta Biosciences, Inc. Mr. Casasanto has a graduate degree from Thomas Jefferson University, an undergraduate degree from the University of Maryland, and an MBA from Lebow College of Business.
Cargos activos de Peter Casasanto
| Empresas | Cargo | Inicio |
|---|---|---|
| SOPHIA GENETICS SA | Corporate Officer/Principal | 10/01/2022 |
Antiguos cargos conocidos de Peter Casasanto.
| Empresas | Cargo | Fin |
|---|---|---|
CellCarta Biosciences, Inc.
 CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | Corporate Officer/Principal | - |
Formación de Peter Casasanto.
| Thomas Jefferson University | Graduate Degree |
| University of Maryland | Undergraduate Degree |
| Lebow College of Business | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SOPHIA GENETICS SA | Technology Services |
| Empresas privadas | 1 |
|---|---|
CellCarta Biosciences, Inc.
CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | Commercial Services |
- Bolsa de valores
- Insiders
- Peter Casasanto
